Bayer reported that its oral factor XIa inhibitor asundexian met the primary endpoint in a Phase 3 trial, reducing recurrent ischemic stroke without increasing major bleeding. The Oceanic Stroke study randomized more than 12,000 patients and compared asundexian plus standard antiplatelet therapy versus placebo plus antiplatelet therapy. Bayer said it will present detailed data at an upcoming scientific meeting and intends to discuss regulatory filings with agencies. The positive top‑line readout revives momentum for FXIa inhibitors after prior setbacks in the class and prompted a double‑digit jump in Bayer shares.